NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
Clinical Trials
10 trialsNCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT07082270 2026-04-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05340309 2026-01-29
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
University of Southern California
Phase 2 Active not recruiting
NCT05455697 2025-12-18
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington
Phase 1/2 Recruiting
NCT04447716 2025-09-15
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
Thomas Jefferson University
Phase 1 Active not recruiting
NCT04659044 2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Terminated
NCT06376214 2024-04-19
Daratumumab for Patients With Light Chain Amyloidosis
Nanjing University School of Medicine
Phase NA Recruiting
NCT04626791 2024-03-12
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT03864419 2024-01-03
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Fred Hutchinson Cancer Center
Phase 1 Terminated